AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-126. (Canceled)

127. (Currently amended) ~~The antisense oligonucleotide of claim 125,~~ An antisense oligonucleotide 20 to 30 nucleobases in length, or a salt form thereof, wherein the antisense oligonucleotide has a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO:247.

128. (Currently amended) The antisense oligonucleotide of claim 127 ~~125~~, wherein the antisense oligonucleotide is 20 nucleobases in length and has a nucleobase sequence consisting of the nucleobase sequence of SEQ ID NO:247.

129. (Currently amended) The antisense oligonucleotide of claim 127 ~~125~~, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

130. (Previously presented) The antisense oligonucleotide of claim 129, wherein the modified internucleoside linkage is a phosphorothioate linkage.

131. (Currently amended) The antisense oligonucleotide of claim 127 ~~125~~, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

132. (Previously presented) The antisense oligonucleotide of claim 131, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

133. (Previously presented) The antisense oligonucleotide of claim 131, wherein the modified sugar moiety is a bicyclic sugar moiety.

134. (Currently amended) The antisense oligonucleotide of claim 127 ~~125~~, wherein the antisense oligonucleotide is a chimeric oligonucleotide having a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.

135. (Previously presented) The antisense oligonucleotide of claim 134, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

136. (Previously presented) The antisense oligonucleotide of claim 134, wherein the modified sugar moiety is a bicyclic sugar moiety.

137. (Currently amended) The antisense oligonucleotide of claim 127 ~~125~~, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

138. (Previously presented) The antisense oligonucleotide of claim 137, wherein the modified nucleobase is a 5-methylcytosine.

139. (Currently amended) The antisense oligonucleotide of claim 127 ~~125~~, wherein the antisense oligonucleotide is a salt form.

140. (Previously presented) The antisense oligonucleotide of claim 139, wherein the salt form is a sodium salt form.

141. (Currently amended) A composition comprising the antisense oligonucleotide of any one of claims ~~125~~ 127 -140 and a pharmaceutically acceptable carrier or diluent.

142. (Previously presented) An antisense oligonucleotide 20 nucleotides in length having the sequence of nucleobases as set forth in SEQ ID NO:247 and comprising 5-methylcytosine at nucleobases 2, 3, 5, 9, 12, 15, 17, 19, and 20, wherein every internucleoside linkage is a phosphorothioate linkage, nucleotides 1-5 and 16-20 are 2'-O-methoxyethyl nucleotides, and nucleotides 6-15 are 2'-deoxynucleotides, or a salt thereof.

143. (Previously presented) The antisense oligonucleotide of claim 142, wherein the antisense oligonucleotide is a salt form.

144. (Previously presented) The antisense oligonucleotide of claim 143, wherein the salt form is a sodium salt form.

145. (Previously presented) A composition comprising the antisense oligonucleotide of any of claims 142 - 144 and a pharmaceutically acceptable carrier or diluent.

146-196. (Canceled)

197. (Previously presented) An antisense compound 12 to 30 nucleobases in length and fully complementary to SEQ ID NO:3, wherein said compound is targeted to the range of nucleotides 3230-3287 as set forth in SEQ ID NO:3, or a salt thereof.

198. (Previously presented) The antisense compound of claim 197, which is 12 to 20 nucleobases in length.

199. (Previously presented) The antisense compound of claim 197, which is an antisense oligonucleotide.

200. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

201. (Previously presented) The antisense oligonucleotide of claim 200, wherein the modified internucleoside linkage is a phosphorothioate linkage.

202. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

203. (Previously presented) The antisense oligonucleotide of claim 202, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

204. (Previously presented) The antisense oligonucleotide of claim 202, wherein the modified sugar moiety is a bicyclic sugar moiety.

205. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide is a chimeric oligonucleotide having a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.

206. (Previously presented) The antisense oligonucleotide of claim 205, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

207. (Previously presented) The antisense oligonucleotide of claim 205, wherein the modified sugar moiety is a bicyclic sugar moiety.

208. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

209. (Previously presented) The antisense oligonucleotide of claim 208, wherein the modified nucleobase is a 5-methylcytosine.

210. (Previously presented) The antisense compound of claim 197, wherein the antisense compound is a salt form.

211. (Previously presented) The antisense compound of claim 210, wherein the salt form is a sodium salt form.

212. (Previously presented) A composition comprising the antisense compound of any one of claims 197-211 and a pharmaceutically acceptable carrier or diluent.

213.-215. (Canceled)

216. (Currently amended) An antisense oligonucleotide 20 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO:247, or a salt form thereof. ~~The antisense oligonucleotide of claim 125 which is 20 nucleobases in length.~~

217. (Previously presented) The antisense oligonucleotide of claim 216, having

a gap segment of ten linked 2'-deoxynucleosides,

a 5' wing segment of five linked nucleosides, and

a 3' wing segment of five linked nucleosides,

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

218. (Previously presented) The antisense oligonucleotide of claim 217, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

219. (Currently amended) The antisense oligonucleotide of claim 218, ~~comprising~~ wherein the modified nucleobase is a 5-methylcytosine.

220. (Previously presented) The antisense oligonucleotide of claim 219, wherein each cytosine is a 5-methylcytosine.

221. (Currently amended) A composition comprising the antisense oligonucleotide of claim ~~125~~ 127 and a penetration enhancer.

222. (Previously presented) The composition of claim 221, wherein the penetration enhancer is capric acid or lauric acid.

223. (Currently amended) A composition comprising the antisense oligonucleotide of claim ~~125~~ 127 and at least one additional pharmaceutically active material.

224. (Currently amended) The composition of claim 223, wherein the at least one additional pharmaceutically active material ~~therapeutic agent~~ is an anti-inflammatory agent.

225. (Previously presented) The composition of claim 145, further comprising at least one additional pharmaceutically active material.

226. (Currently amended) The composition of claim 225, wherein the at least one additional pharmaceutically active material ~~therapeutic agent~~ is an anti-inflammatory agent.

227. (Previously presented) The antisense oligonucleotide of claim 197, which is 20 nucleobases in length.

228. (Previously presented) The antisense oligonucleotide of claim 227, having

a gap segment of ten linked 2'-deoxynucleosides,

a 5' wing segment of five linked nucleosides, and

a 3' wing segment of five linked nucleosides,

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

229. (Previously presented) The antisense oligonucleotide of claim 228, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

230. (Previously presented) The antisense oligonucleotide of claim 229, comprising at least one modified cytosine, wherein the cytosine is a 5-methylcytosine.

231. (Previously presented) The antisense oligonucleotide of claim 230, wherein each cytosine is a 5-methyl cytosine.

232. (Previously presented) An oral formulation comprising the antisense compound of claim 197 and a pharmaceutically acceptable diluent or carrier.

233. (Previously presented) The formulation of claim 232, wherein said formulation comprises a penetration enhancer.

234. (Previously presented) The composition of claim 233, wherein the penetration enhancer is capric acid or lauric acid.

235. (Previously presented) A composition comprising the antisense oligonucleotide of claim 197 and at least one additional pharmaceutically active material.

236. (Currently amended) The composition of claim 235, wherein the at least one additional pharmaceutically active material ~~therapeutic agent~~ is an anti-inflammatory agent.

237. (Previously presented) The antisense oligonucleotide of claim 133, wherein the bicyclic sugar moiety has a $(-CH_2-)_n$ group forming a bridge between the 2' oxygen ant the 4' carbon atoms of the sugar ring, wherein n is 1 or 2.

238. (Previously presented) The antisense oligonucleotide of claim 136, wherein the bicyclic sugar moiety has a $(-CH_2-)_n$ group forming a bridge between the 2' oxygen ant the 4' carbon atoms of the sugar ring, wherein n is 1 or 2.

239. (Previously presented) The antisense oligonucleotide of claim 204 wherein the bicyclic sugar moiety has a $(-CH_2-)_n$ group forming a bridge between the 2' oxygen ant the 4' carbon atoms of the sugar ring, wherein n is 1 or 2.

240. (Previously presented) The antisense oligonucleotide of claim 207 wherein the bicyclic sugar moiety has a $(-CH_2-)_n$ group forming a bridge between the 2' oxygen ant the 4' carbon atoms of the sugar ring, wherein n is 1 or 2.

241. (New) The antisense oligonucleotide of claim 216, wherein the antisense oligonucleotide is fully complementary to SEQ ID NO:3.

242. (New) The antisense oligonucleotide of claim 127, having

a gap segment of ten linked 2'-deoxynucleosides,

a 5' wing segment of five linked nucleosides, and

a 3' wing segment of five linked nucleosides,

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

243. (New) A composition comprising the antisense oligonucleotide of claim 142 and a penetration enhancer.

244. (New) The composition of claim 243, wherein the penetration enhancer is capric acid or lauric acid.

245. (New) A composition comprising the antisense oligonucleotide of claim 216 and a penetration enhancer.

246. (New) The composition of claim 245, wherein the penetration enhancer is capric acid or lauric acid.